Revolution Medicines Officer Plans $3.6M Stock Sale via 10b5-1
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Revolution Medicines Officer Plans $3.6M Stock Sale via 10b5-1
Company: Revolution Medicines, Inc. Form: 144 | Filed: 2026/03/26 Significance: Low
Insider: Mancini Anthony Relationship: Officer
Transaction: • Type: Proposed Sale • Shares: 37,450 • Price: ~$95.56 (Implied) • Value: $3,578,823
Key Insight: Officer proposes sale of shares acquired via option exercise under a 10b5-1 plan adopted in Dec 2025. Transaction represents <0.02% of market cap.
Market Context: Transaction is routine and immaterial relative to the company's $18.8B market capitalization.
Comprehensive Analysis
SEC Filing Analysis: Revolution Medicines, Inc.
Executive Summary
- Trading Significance: Low
- Key Takeaway: Officer Anthony Mancini initiates a routine 10b5-1 planned sale of ~$3.6M in stock derived from option exercises.
- Market Impact: Neutral; the transaction size is negligible relative to the company's $18.8B valuation.
Company Information
| Field | Value |
|---|---|
| Company | Revolution Medicines, Inc. |
| CIK | 0001628171 |
| Industry | Biological Products |
Insider Information
| Field | Value |
|---|---|
| Name | Mancini Anthony |
| CIK | 0002124509 |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Approx Sale Date | 03/25/2026 |
| Security Type | Common Stock |
| Shares Involved | 37,450 |
| Price Per Share | ~$95.56 (Calculated) |
| Total Value | $3,578,823.12 |
| Acquisition Source | Stock Option Exercise |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $3,578,823.12 |
| % of Market Cap | 0.019% |
| Shares Transacted | 37,450 |
| % of Shares Outstanding | 0.019% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market cap of $18.80 billion, a $3.6M transaction is mathematically insignificant (less than 0.02%).
- Dilution Impact: The shares sold originate from stock options (Right to Buy) acquired on 04/01/2025. While option exercises technically increase the float, the volume here (0.019% of outstanding) creates no meaningful dilution pressure.
- Transaction Significance: The transaction falls well below the 0.1% threshold for moderate significance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale is conducted under a 10b5-1 trading plan adopted on 12/24/2025. Planned sales of this magnitude relative to the company's size are standard compensation liquidation events and do not signal bearish sentiment.
Volume & Sentiment
- Expected Volume Impact: Negligible.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Special Circumstances: The sale is pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. This pre-planned nature insulates the trade from immediate market sentiment or non-public information.
- Source of Shares: Shares were acquired via "Stock Option (Right to Buy)" as payment for services rendered.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.